Finanzen von Syndax Pharmaceuticals Inc (SNDX)SNDXSyndax Pharmaceuticals Inc

Evaluating the bottom line, Syndax Pharmaceuticals, Inc. maintains a gross margin of 95.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -53.90%, while the net margin is -66.86%. These profitability ratios, combined with a Return on Equity (ROE) of -255.93%, provide a clear picture of how effectively SNDX converts its operational activities into shareholder value.

In the context of the broader market, SNDX competes directly with industry leaders such as IAM and CTY. With a market capitalization of $1.21B, it holds a leading position in the sector. When comparing efficiency, SNDX's gross margin of 95.76% stands against IAM's N/A and CTY's N/A. Such benchmarking helps identify whether Syndax Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Syndax's financial performance shows a narrowing net loss of $49.36 million in Q2 2026, but the company has consistently reported negative net income and high debt levels. Gross margins remain strong at around 95% but are overshadowed by operational losses.